Tina-quant® C-Reactive Protein

CRP using DuREL technology offers outstanding performance

Tina-quant® C-Reactive Protein

Tina-quant® C-Reactive Protein1-8


C‑reactive protein is the classic acute phase protein in inflammatory reactions. It is synthesised by the liver and consists of five identical polypeptide chains that form a five‑membered ring having a molecular weight of 105000 daltons. 

CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. Complexed CRP activates the classical complement pathway. The CRP response frequently precedes clinical symptoms, including fever.

In normal healthy individuals CRP is a trace protein with a range up to 5 mg/L. After onset of an acute phase response the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis). CRP response may be less pronounced in patients suffering from liver disease. 



CRP assays are used to detect systemic inflammatory processes; to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti‑inflammatory therapy; to determine the presence of post‑operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow rejection. Postoperative monitoring of CRP levels of patients can aid in the recognition of unexpected complications (persisting high or increasing levels). 

Measuring changes in the concentration of CRP provides useful diagnostic information about how acute and how serious a disease is. It also allows judgements about the disease genesis. Persistence of a high serum CRP concentration is usually a grave prognostic sign which generally indicates the presence of an uncontrolled infection.

Woman in Lab
Innovation for medical value
Roche continues to invest significantly in medical value. Innovations include new technologies for superior performance; generating new claims for existing assays for wider application; and advancing assay design for accurate and reliable measurements, to help clinicians and patients. 



For more information


New assay format based on expertise and innovation, e.g. DuREL for improvement of analytical sensitivity and extension of measuring range

Tina-quant® C-Reactive Protein Gen.3 Graph

Figure: With the introduction of the Tina-quant® C-Reactive Protein Gen.3 using dual-radius enhanced latex (DuREL) technology, Roche Diagnostics has set a new milestone for accuracy and sensitivity of CRP managements.

The Tina-quant® C-Reactive Protein assay and application is designed to achieve the very high sensitivity, offering a very accurate and precise measurements at very low levels of CRP.
Measurement of CRP is of use for diagnosis and management of infection, assessment of inflammation.
Whereas highly sensitive measurement of CRP is used as an aid in the assessment of the risk of future cardio- and peripheral vascular disease.
  1. CRP Gen.1, Gen.2 & Gen.3 package inserts. Roche Diagnostics. 2019.   
  2. Data on file. Roche Diagnostics (2019). Roche 3D tool YE 2018 
  3. Calculated using data on file. Roche Diagnostics (2019).


  1. Greiling, H., Gressner, A.M., eds. (1995). Lehrbuch der Klinischen Chemie und Pathobiochemie, 3rd ed. Stuttgart/New York: Schattauer Verlag, 234-236.
  2. Thomas, L. (2008). Labor und Diagnose, 7. Auflage, TH-Books Verlagsgesellschaft mbH, Frankfurt/Main, 1010-1021.
  3. Burtis, C.A., Ashwood, E.R., eds. (2001). Tietz Fundamentals of Clinical Chemistry, 5th ed. Pa: WB Saunders Co, 332-333.
  4. Thomas, L., Messenger, M. (1993). Pathobiochemie und Labordiagnostik der Entzündung. Lab med 17, 179-194.
  5. Young, B., Gleeson, M., Cripps, A.W. (1991). C-reactive protein: A critical review. Pathology 23, 118-124.
  6. Wasunna, A., Whitelaw, A., Gallimore, R., et al. (1990). C-reactive protein and bacterial infection in preterm infants. Eur J Pediatr Mar 149(6):424-427.
  7. Vergis, N. (2007). Should CRP be used as a marker of infection in patients with liver cirrhosis? Clin Lab Int 6, 12-13.
  8. Mackenzie, I., Woodhouse, J. (2006). C-reactive protein concentrations during bacteraemia: a comparison between patients with and without liver dysfunction. Intensive Care Medicine 32, 1344-1351.